Evolus (EOLS) Current Assets (2017 - 2026)
Evolus' (EOLS) quarterly Current Assets came in at $138.9 million in Q1 2026, up 5.47% YoY from $131.7 million in Q1 2025, and down 2.79% on a QoQ basis from $142.9 million in Q4 2025.
Evolus (EOLS) Current Assets (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Current Assets data on file, last reported at $138.9 million in Q1 2026.
- Quarterly Current Assets rose 5.47% year-over-year to $138.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.9 million (up 5.47% YoY) and the FY2025 annual result came in at $142.9 million, down 5.57% from the prior year.
- Current Assets fell to $138.9 million in Q1 2026, from $142.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $158.1 million in Q2 2024 to a low of $84.1 million in Q1 2023.
- A 5-year average of $128.4 million and a median of $134.9 million in 2025 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 83.91% in 2022, down 43.62% in 2022.
- Tracing EOLS's Current Assets over 5 years: stood at $100.8 million in 2022, then rose by 11.53% to $112.4 million in 2023, then soared by 34.62% to $151.3 million in 2024, then decreased by 5.57% to $142.9 million in 2025, then declined by 2.79% to $138.9 million in 2026.
- The last three Current Assets figures came in at $138.9 million (Q1 2026), $142.9 million (Q4 2025), and $134.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.23 Bn | 43.26 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.87 Bn | 40.22 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 32.48 Bn | 30.80 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.23 Bn | 19.57 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.87 Bn | 17.99 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.96 Bn | 11.43 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 3.22 Bn |
| 10 | Evolus | 548.86 Mn | 503.69 Mn | 57.18 Mn | 167.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 167.54 Mn |
| Mar 31, 2026 | 138.92 Mn |
| Dec 31, 2025 | 142.92 Mn |
| Sep 30, 2025 | 134.89 Mn |
| Jun 30, 2025 | 144.97 Mn |
| Mar 31, 2025 | 131.72 Mn |
| Dec 31, 2024 | 151.34 Mn |
| Sep 30, 2024 | 150.36 Mn |
| Jun 30, 2024 | 158.13 Mn |
| Mar 31, 2024 | 150.27 Mn |
| Dec 31, 2023 | 112.42 Mn |
| Sep 30, 2023 | 92.00 Mn |
| Jun 30, 2023 | 96.46 Mn |
| Mar 31, 2023 | 84.09 Mn |
| Dec 31, 2022 | 100.80 Mn |
| Sep 30, 2022 | 115.95 Mn |
| Jun 30, 2022 | 133.95 Mn |
| Mar 31, 2022 | 142.93 Mn |
| Dec 31, 2021 | 178.80 Mn |
| Sep 30, 2021 | 138.34 Mn |